Related Experiment Video
Updated: Feb 24, 2026

Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma
Andrea Kühnl1, David Cunningham1, Ian Chau1
1Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
Abstract:
After decades of intense research on genetic alterations in cancer and successful implementation of genetically-based targeted therapies, the field of cancer epigenetics is only beginning to be fully recognized. The discovery of frequent mutations in genes modifying the epigenome in diffuse large B-cell lymphoma (DLBCL) has highlighted the outstanding role of epigenetic deregulation in this disease. Identification of epigenetically-driven DLBCL subgroups and development of novel epigenetic drugs have rapidly advanced. However, further insights are needed into the biological consequences of epigenetic alterations and the possibility of restoring the aberrant epigenome with specific therapies to bring this treatment concept further into clinical practice. This review will summarize the main epigenetic changes found in DLBCL and their potential for precision medicine approaches.
More Related Videos
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017
10:41An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
Published on: April 5, 2018
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Epigenetic Regulation
X-chromosome...
Pharmacogenomics: Identification of New Drug Targets